For the side effect nobody warns you about
GLP-1 therapy has a sexual side effect that gets discussed far less than the nausea, and in our experience it is the one that actually makes people quit: orgasm becoming delayed, muted, or not arriving at all. It creeps up over weeks, so people often do not connect it to the drug — and when they do, the usual advice is to reduce the dose and accept losing ground.
SuperCLIMAX exists because there is a second option. The dysfunction has two components, and this vial addresses both of them with two compounds that do different jobs.
Two things break, not one
The first published case report attributing anorgasmia specifically to GLP-1 therapy (Visvabharathy, Sexual Medicine, 2025) attributes the mechanism to reduced hypothalamic dopamine and norepinephrine signalling arising from GLP-1 receptor modulation. That is the same reward pathway the appetite suppression works through, which is the uncomfortable part: the mechanism that makes food less interesting is not confined to food.
Dopaminergic signalling can fail in two distinct places, and this appears to hit both:
- Less dopamine gets released. The upstream signal is suppressed, so there is less to work with.
- Receptors respond less to what is released. Even the available dopamine produces a weaker downstream effect.
A compound that only fixed one of those would be working against the other. Add dopamine release to unresponsive receptors and much of it is wasted; sensitise receptors with nothing arriving and there is nothing to amplify. That is why this is a two-compound formulation rather than a higher dose of either one.
PT-141 — from the brain, not the blood vessels
Bremelanotide is a melanocortin-4 receptor agonist and it is FDA-approved as Vyleesi for hypoactive sexual desire disorder, at 1.75 mg subcutaneously. That approval matters: it means there is human trial data behind the compound rather than mechanism alone, and a known dose and side-effect profile.
The important distinction is where it acts. PDE5 inhibitors work on blood flow — they address mechanics. PT-141 acts centrally: research describes MC4R activation in the brain as driving mesolimbic dopamine release in the nucleus accumbens. It addresses wanting, not plumbing, which is why it is the relevant tool when the problem is a suppressed reward pathway rather than circulation.
And because it drives dopamine release through the melanocortin system rather than the GLP-1 system, it bypasses the suppression instead of arguing with it. The GLP-1 agonist is still doing what it does. This opens a different door into the same room.
Our dose is 2 mg, marginally above the approved 1.75 mg — within the range with demonstrated efficacy and a manageable nausea profile. Research describes peak plasma at around one hour subcutaneously with onset near 45 minutes, which is what sets the timing instruction.
MIF-1 — turning up the receiver, not the transmitter
MIF-1 is an endogenous brain tripeptide — Pro-Leu-Gly-NH₂, also written PLG. It is not a dopamine agonist and that distinction is the whole reason it is in the vial. Research describes it as a positive allosteric modulator at the D2 and D4 dopamine receptor subtypes: it binds a site separate from where dopamine binds and increases the receptor's binding affinity for agonists, making it more responsive to stimulation.
A direct dopamine agonist activates the receptor whether or not dopamine is present. That is how the dopaminergic drugs associated with compulsive behaviour work, and it is a genuine risk with that class.
A positive allosteric modulator does nothing on its own. It has no effect until endogenous dopamine arrives, and then it amplifies the response to it. There is no receptor activation without your own signal to activate it — which is why the literature does not describe MIF-1 with the compulsion or dependence profile associated with direct agonists. It cannot create a signal. It can only make the one you have count for more.
It is also unusually well-suited to being given this way. Research describes MIF-1 as notably resistant to metabolism in the bloodstream and as crossing the blood-brain barrier readily — uncommon for a peptide, and the reason a subcutaneous dose reaches central receptors at all. Its plasma half-life is around five days, so with repeated use there is residual accumulation between doses. That is a feature rather than a problem: receptor sensitisation persists between occasions.
The compound is not new or obscure. Ehrensing and Kastin identified it as an antidepressant decades ago, and clinical work has examined it in Parkinson's disease and depression. Our 50 mg per dose sits at roughly two-thirds of the 75 mg daily dose reported as effective for depression in that older literature — well inside a range that has been given to people.
One compound supplies the signal, the other restores the hearing
| What GLP-1 does | What answers it | How |
|---|---|---|
| Reduces dopamine release | PT-141 | Drives release through the melanocortin system, bypassing the suppressed pathway |
| Reduces receptor responsiveness | MIF-1 | Allosterically raises D2/D4 affinity, so what is released does more |
The two are multiplicative rather than additive. More dopamine arriving at more responsive receptors is a different proposition from either change alone — and it is why the vial contains a modest dose of each rather than a large dose of one.
One point worth pre-empting, because a careful reader will notice it: MIF-1 is named for inhibiting the release of melanocyte-stimulating hormone, and PT-141 is a melanocortin agonist — which looks like a contradiction. It is not. PT-141 acts directly on the MC4 receptor as an exogenous agonist; it does not depend on endogenous MSH being released to do so. The two act on different points and do not cancel.
Five doses, taken only when needed
| Active | Per vial | Per dose | Role |
|---|---|---|---|
| MIF-1 (Pro-Leu-Gly-NH₂) | 250 mg | 50 mg | D2/D4 positive allosteric modulator — restores receptor responsiveness |
| PT-141 (Bremelanotide) | 10 mg | 2 mg | MC4R agonist — drives central dopamine release |
This is an as-needed product, not a daily one. One dose roughly 45 minutes ahead, maximum one in 24 hours. Five full doses per cartridge is a month at heavy use and considerably longer at typical use — which is exactly why the argon seal matters here more than on a daily product. This cartridge will be open a long time.
The cartridge also supports a half dose at 0.3 mL — 25 mg of MIF-1 with 1 mg of PT-141 — which doubles it to ten. Worth knowing that 1 mg of PT-141 falls below the 1.75 mg approved dose, so the full 0.6 mL is the intended one. The half exists for titration, or for anyone who finds the full dose brings more nausea than they want.
Two compounds that want opposite things
This vial was harder to build than its two-ingredient list suggests, because the actives have incompatible preferences. PT-141 is a cationic peptide: it aggregates if you give it the chelators and organic acids that stabilise most formulations, so the vehicle here carries none of them. MIF-1 is a small hydrophobic tripeptide present at 500 mg, twenty- five times the mass of the PT-141, and at that loading it brings problems of its own.
A test vial at full MIF-1 loading showed filtration problems — the signature of a compound beginning to associate with itself rather than staying in solution. The resolution was an amino acid added as an aggregation suppressor, which shields MIF-1's hydrophobic side chain and competes for the counter-ion pairing the raw material brings with it. The same fix is used in commercial tesamorelin formulations. It was added in July 2026, after the bench told us it was needed rather than before. Filtration behaviour reveals solubility and aggregation problems before they ever reach a vial — which is the entire reason we watch it.
A surfactant is present for PT-141's filter compatibility, and an antioxidant amino acid protects its oxidation-sensitive residue and guards against trace copper contamination. MIF-1 needs neither, but neither interferes with it.
MIF-1 is a tripeptide with a molecular weight under 300, and osmolality counts particles rather than mass. That makes it disproportionately powerful at raising the tonicity of a solution: at the loading we originally ran, it contributed almost 60% of the total on its own, before a single excipient, and the cartridge came out at roughly three and a half times plasma. That is a solution that stings.
The obvious fix — reconstitute into more water — is not available to us. Everything here is built around a 3 mL pen cartridge, and a 3 mL cartridge cannot hold 5 mL. So we halved what goes into it instead. Same 50 mg of MIF-1 and 2 mg of PT-141 per dose, drawn as 0.6 mL instead of 0.3 mL, at roughly 535 mOsm/kg — about 1.9 times plasma rather than 3.5.
The cost is doses per cartridge: five instead of ten. For a compound taken before anticipated intimacy, at most once in twenty-four hours, five doses is a month of heavy use. We would rather sell a cartridge that is comfortable to inject than one that lasts twice as long and is unpleasant every time.
The standard advice is to lower the dose and accept losing ground. There is another option, and it addresses the actual mechanism rather than retreating from it.
All custom blends